More Countries Have AMR Plans, but Patients Lack Tests, Treatment

As more countries are taking steps to tackle antimicrobial resistance (AMR), major gaps that remain in testing and treatment mean that many patients are still at risk, according to new data from the World Health Organization (WHO).

When medicines lose their effectiveness against resistant bacteria and other microbes, common infections become harder to treat and routine medical procedures, including surgery, childbirth and cancer care, become riskier. In 2023, approximately 1 in 6 laboratory-confirmed bacterial infections worldwide were resistant to antibiotics, highlighting the growing threat to patients.

The new findings released today ahead of World AMR Awareness Week , show that 173 countries report having developed plans to address AMR, more than double the 79 countries that reported doing so in 2017.

But having a plan does not necessarily mean patients are protected. Only 22% of countries report having both the necessary funding and full implementation of national AMR action plans. This leaves major gaps worldwide along the pathway of care, from preventing infections to diagnosing and treating patients, as well as detecting resistance trends and taking control measures.

"National plans are essential for protecting the medicines that protect us, and the fact that most countries now have plans in place is great news," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "But an unfulfilled plan helps no one. We call on all countries to implement their plans with investments in infection prevention, surveillance, equitable access to essential antimicrobials and quality diagnostics. Every infection prevented means fewer antimicrobials are needed, and testing ensures that patients receive the right treatment only when necessary.

The findings are included in the latest Tracking Antimicrobial Resistance Country Self-assessment Survey (TrACSS), completed by 183 countries (94% of Member States) in 2026.

Diagnostic capacity falls short where patients need it most

Access to diagnostic testing helps ensure patients receive the right treatment at the right time. However, such testing is inadequate in most countries. Only 36% of countries report having a national reference laboratory equipped to test the selected bacteria and fungi. This falls far short of the global target of 80% of countries having comprehensive bacterial and fungal resistance testing capacity by 2030.

Inadequate access to diagnostic tests increases the risk of patients being prescribed antibiotics that are ineffective or unnecessary. Resistant infections and outbreaks may go undetected, while gaps in surveillance data limit understanding of local resistance patterns.

The gaps extend further to treatment guidelines and surveillance. Only 63% of countries report having guidelines on appropriate use of antimicrobials, and just over half report having surveillance systems to monitor national antibiotic use and track levels of AMR.

To help countries close the gaps, WHO released two new practical tools as part of the AMR Diagnostic Initiative. The tools provide a prioritized catalogue of diagnostic tests and step-by-step methods to help clinical laboratories diagnose bacterial and fungal infections.

Raising awareness and accelerating action

World AMR Awareness Week, held 18–24 November, is a global campaign to raise awareness of AMR and promote action to prevent the emergence and spread of drug-resistant infections. Under the 2026 theme, "One Health, one action: Prevent AMR now", the campaign highlights the interconnected health of people, animals, plants and the environment, and calls on everyone – from governments to farmers, veterinarians, environmental experts and communities – to take action to prevent AMR.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.